View Clause Headings                                                                                                                                               HelpHelp
DOCUMENT TITLE:  TRADEMARK LICENSE AGREEMENT .
ACTIONS: Here are the clause headings in the document. To view the clause, click the clause heading.To view the full document, click the "View Document" button.

View Document Back
Clause Heading
2.1 - Conditions Precedent.
3.1 - Licensed Trademarks.
3.2 - Sub-Licenses.
3.3 - Co-Promoting.
4.1 - Events.
4.2 - Payment Terms.
5.1 - Rates.
5.2 - Significant Generic Competition.
5.3 - Combination Products.
6.1 - Timing.
6.2 - Statement.
7.1 - Trademark Milestone Notification.
7.2 - Accounting.
7.3 - Running Royalties Reporting.
7.4 - Late Payment Interest.
8.1 - Payments.
8.2 - Withholding Taxes.
8.3 - Audits.
8.4 - Amicable Settlement.
8.5 - CNRS Rights.
9.1 - Undertakings.
9.2 - Branding.
9.3 - Prior Approval.
9.4 - License Disclosure.
10.1 - Commercialization.
11.1 - Registration.
11.2 - Filing Information.
11.3 - Cooperation.
12.1 - Suing Rights.
12.2 - Mutual Information.
13.1 - Third Party Claims.
13.2 - Cost Sharing.
13.3 - Orders and Injunctions.
14.1 - ImmuPharma Technical Information.
14.2 - Anesta Technical Information.
14.3 - Survival and Applicability.
15.1 - This Agreement.
15.2 - Press Releases.
15.3 - Listing and other Required Publicity.
15.4 - Recordation of Licensed Trademarks.
16.1 - Representations and Warranties.
(B) - ImmuPharma Switzerland is not insolvent;
17.1 - Representations and Warranties.
18.1 - By ImmuPharma Switzerland.
18.2 - By Anesta.
18.3 - Notifications.
18.4 - Assistance.
18.5 - Joint Liability.
19 - Insurance
20.1 - EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT AND TO THE FULLEST EXTENT PERMITTED BY LAW:
(A) - IMMUPHARMA SWITZERLAND MAKES NO WARRANTY OR REPRESENTATION AS TO THE SCOPE OF THE LICENSED TRADEMARKS;
21.1 - Ordinary Termination.
21.2 - Consequences of Ordinary Termination.
21.3 - Survival Upon Ordinary Termination.
(A) - This Agreement.
22.1 - Specific Performance.
22.2 - Breach.
22.3 - Extraordinary Termination of Development and Commercialization Agreement.
22.4 - Cross Breach Under Parent Guarantee Agreement.
22.5 - Insolvency or Bankruptcy.
(A) - Anesta.
(B) - ImmuPharma.
22.7 - General Extraordinary Termination Right of Anesta.
22.8 - Written Termination Agreement.
22.9 - Ordinary Termination of Development and Commercialization Agreement.
23.1 - Existing Obligations.
24.1 - Early Termination by ImmuPharma.
24.2 - Early Termination Due to Ordinary Termination of Development and Commercialization Agreement.
24.3 - Early Termination by Anesta.
24.4 - Survival Upon Extraordinary Termination.
24.5 - Marketing.
25.1 - Non-Assignability.
25.2 - Exception.
26.1 - Affiliates, Sub-Licensees and Third Parties.
26.2 - Liability.
27.1 - Development and Commercialization Agreement.
28.1 - Applicability.
28.2 - Amicable Settlement.
28.3 - Mediation.
28.4 - Mediation Notice.
28.5 - Arbitration.
28.6 - Injunctive Relief.
29.1 - No Limitations.
29.2 - Enforcement.
30 - General Assurances
31 - Severability
32 - Entire Agreement
33 - Titles and Headings
34 - Costs of Preparation
35 - Notices
36 - Force Majeure
37 - No Agency, Partnership or Joint Venture
38 - Benefit to Third Parties
39 - Governing Law